ArticleFrontiers in oncology2025
Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study is to investigate whether the therapeutic efficacy of bevacizumab (BEV) in the treatment of high-grade glioma (HGG) is associated with the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) on the basis of excluding the interference from chemotherapy drugs. Methods: This study included 57 patients with histologically confirmed HGG who, due to various reasons, were unable to complete the standard chemotherapy protocol and thus received BEV treatment. Patients enrolled in the study were divided into two groups based on their MGMT status: the unmethylated MGMT group and the methylated MGMT group. Depending on whether the numerical variables of the patients satisfied a normal distribution, either the T-test or the rank-sum test was employed. For the comparison of categorical variables, the chi-square test was used. Results: After BEV treatment, both PFS and OS were higher in the methylated MGMT group compared to the unmethylated group. Additionally, the tumor control rate was also higher in the methylated group. Furthermore, in both patient groups, a decrease in steroid dosage was observed following BEV treatment, accompanied by an increase in KPS. Multivariate COX regression analysis revealed that radiotherapy and complete tumor resection were significant factors influencing PFS and OS in HGG patients. Additionally, pathological grade was found to influence PFS in HGG patients. Conclusion: Based on the exclusion of the interference from chemotherapy drugs, our study is the first to confirm the correlation between the methylation status of MGMT and the therapeutic effect of BEV on HGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.